New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance

C. Lipina, W. Rastedt, A.J. Irving, H.S. Hundal

    Research output: Contribution to journalArticle

    14 Citations (Scopus)

    Abstract

    Growing evidence suggests that pathological overactivation of the endocannabinoid system (ECS) is associated with dyslipidemia, obesity and diabetes. Indeed, this signalling system acting through cannabinoid receptors has been shown to function both centrally and peripherally to regulate feeding behaviour as well as energy expenditure and metabolism. Consequently, modulation of these receptors can promote significant alterations in body weight and associated metabolic profile. Importantly, blocking cannabinoid receptor type 1 function has been found to prevent obesity and metabolic dysfunction in various murine models and in humans. Here we provide a detailed account of the known physiological role of the ECS in energy balance, and explore how recent studies have delivered novel insights into the potential targeting of this system as a therapeutic means for treating obesity and related metabolic disorders. The endocannabinoid system (ECS) plays an important role in the regulation of energy metabolism. Its pathological overactivation seems to be associated with dyslipidemia, obesity and diabetes. Targeting the ECS may therefore provide a therapeutic means for treating obesity and related metabolic disorders.
    Original languageEnglish
    Pages (from-to)681-691
    Number of pages11
    JournalBioEssays
    Volume34
    Issue number8
    DOIs
    Publication statusPublished - 1 Aug 2012

    Fingerprint

    Endocannabinoids
    Medical problems
    Energy balance
    Metabolism
    Obesity
    Modulation
    Cannabinoid Receptors
    Energy Metabolism
    Dyslipidemias
    Metabolome
    Feeding Behavior
    Body Weight
    Therapeutics

    Cite this

    @article{5ead5b21817e47fc8321183d97038775,
    title = "New vistas for treatment of obesity and diabetes?: Endocannabinoid signalling and metabolism in the modulation of energy balance",
    abstract = "Growing evidence suggests that pathological overactivation of the endocannabinoid system (ECS) is associated with dyslipidemia, obesity and diabetes. Indeed, this signalling system acting through cannabinoid receptors has been shown to function both centrally and peripherally to regulate feeding behaviour as well as energy expenditure and metabolism. Consequently, modulation of these receptors can promote significant alterations in body weight and associated metabolic profile. Importantly, blocking cannabinoid receptor type 1 function has been found to prevent obesity and metabolic dysfunction in various murine models and in humans. Here we provide a detailed account of the known physiological role of the ECS in energy balance, and explore how recent studies have delivered novel insights into the potential targeting of this system as a therapeutic means for treating obesity and related metabolic disorders. The endocannabinoid system (ECS) plays an important role in the regulation of energy metabolism. Its pathological overactivation seems to be associated with dyslipidemia, obesity and diabetes. Targeting the ECS may therefore provide a therapeutic means for treating obesity and related metabolic disorders.",
    author = "C. Lipina and W. Rastedt and A.J. Irving and H.S. Hundal",
    note = "Copyright 2012 Elsevier B.V., All rights reserved.",
    year = "2012",
    month = "8",
    day = "1",
    doi = "10.1002/bies.201200031",
    language = "English",
    volume = "34",
    pages = "681--691",
    journal = "BioEssays",
    issn = "0265-9247",
    publisher = "Wiley-VCH",
    number = "8",

    }

    New vistas for treatment of obesity and diabetes? Endocannabinoid signalling and metabolism in the modulation of energy balance. / Lipina, C.; Rastedt, W.; Irving, A.J.; Hundal, H.S.

    In: BioEssays, Vol. 34, No. 8, 01.08.2012, p. 681-691.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - New vistas for treatment of obesity and diabetes?

    T2 - Endocannabinoid signalling and metabolism in the modulation of energy balance

    AU - Lipina, C.

    AU - Rastedt, W.

    AU - Irving, A.J.

    AU - Hundal, H.S.

    N1 - Copyright 2012 Elsevier B.V., All rights reserved.

    PY - 2012/8/1

    Y1 - 2012/8/1

    N2 - Growing evidence suggests that pathological overactivation of the endocannabinoid system (ECS) is associated with dyslipidemia, obesity and diabetes. Indeed, this signalling system acting through cannabinoid receptors has been shown to function both centrally and peripherally to regulate feeding behaviour as well as energy expenditure and metabolism. Consequently, modulation of these receptors can promote significant alterations in body weight and associated metabolic profile. Importantly, blocking cannabinoid receptor type 1 function has been found to prevent obesity and metabolic dysfunction in various murine models and in humans. Here we provide a detailed account of the known physiological role of the ECS in energy balance, and explore how recent studies have delivered novel insights into the potential targeting of this system as a therapeutic means for treating obesity and related metabolic disorders. The endocannabinoid system (ECS) plays an important role in the regulation of energy metabolism. Its pathological overactivation seems to be associated with dyslipidemia, obesity and diabetes. Targeting the ECS may therefore provide a therapeutic means for treating obesity and related metabolic disorders.

    AB - Growing evidence suggests that pathological overactivation of the endocannabinoid system (ECS) is associated with dyslipidemia, obesity and diabetes. Indeed, this signalling system acting through cannabinoid receptors has been shown to function both centrally and peripherally to regulate feeding behaviour as well as energy expenditure and metabolism. Consequently, modulation of these receptors can promote significant alterations in body weight and associated metabolic profile. Importantly, blocking cannabinoid receptor type 1 function has been found to prevent obesity and metabolic dysfunction in various murine models and in humans. Here we provide a detailed account of the known physiological role of the ECS in energy balance, and explore how recent studies have delivered novel insights into the potential targeting of this system as a therapeutic means for treating obesity and related metabolic disorders. The endocannabinoid system (ECS) plays an important role in the regulation of energy metabolism. Its pathological overactivation seems to be associated with dyslipidemia, obesity and diabetes. Targeting the ECS may therefore provide a therapeutic means for treating obesity and related metabolic disorders.

    UR - http://www.scopus.com/inward/record.url?scp=84863880828&partnerID=8YFLogxK

    U2 - 10.1002/bies.201200031

    DO - 10.1002/bies.201200031

    M3 - Article

    C2 - 22674489

    AN - SCOPUS:84863880828

    VL - 34

    SP - 681

    EP - 691

    JO - BioEssays

    JF - BioEssays

    SN - 0265-9247

    IS - 8

    ER -